Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioScience Health Innovations (BHIC) Current Deferred Revenue (2023 - 2025)

Historic Current Deferred Revenue for BioScience Health Innovations (BHIC) over the last 3 years, with Q3 2025 value amounting to $110991.0.

  • BioScience Health Innovations' Current Deferred Revenue changed N/A to $110991.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $110991.0, marking a year-over-year change of. This contributed to the annual value of $24329.0 for FY2024, which is 51608.0% up from last year.
  • BioScience Health Innovations' Current Deferred Revenue amounted to $110991.0 in Q3 2025.
  • BioScience Health Innovations' Current Deferred Revenue's 5-year high stood at $248659.0 during Q2 2025, with a 5-year trough of $3949.0 in Q4 2023.
  • For the 3-year period, BioScience Health Innovations' Current Deferred Revenue averaged around $87593.2, with its median value being $50038.0 (2025).
  • Data for BioScience Health Innovations' Current Deferred Revenue shows a peak YoY increase of 51608.0% (in 2024) and a maximum YoY decrease of 51608.0% (in 2024) over the last 5 years.
  • Over the past 3 years, BioScience Health Innovations' Current Deferred Revenue (Quarter) stood at $3949.0 in 2023, then soared by 516.08% to $24329.0 in 2024, then soared by 356.21% to $110991.0 in 2025.
  • Its last three reported values are $110991.0 in Q3 2025, $248659.0 for Q2 2025, and $50038.0 during Q1 2025.